Drugs & Targets FDA clears IND application for ZW171, a 2+1 T-cell targeting bispecific antibody for mesothelin-expressing cancers June 21, 2024Vol.50 No.25
Drugs & Targets FDA approves Breyanzi for relapsed or refractory mantle cell lymphoma June 14, 2024Vol.50 No.24
Drugs & Targets FDA grants accelerated approval to Augtyro for NTRK gene fusion-positive solid tumors June 14, 2024Vol.50 No.24
In Brief Harpreet Singh departs FDA, joins Precision for Medicine as chief medical officer June 07, 2024Vol.50 No.23
Drugs & Targets FDA approves imetelstat for low- to intermediate-1 risk MDS with transfusion-dependent anemia June 07, 2024Vol.50 No.23
Drugs & Targets FDA grants accelerated approval to selpercatinib for pediatric RET-altered metastatic thyroid cancer or solid tumors May 31, 2024Vol.50 No.22
Drugs & Targets FDA acknowledges BLA resubmission for Zolbetuximab for HER2- gastric or GEJ adenocarcinoma with CLDN18.2-positive tumors May 31, 2024Vol.50 No.22
Drugs & Targets FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening May 24, 2024Vol.50 No.21
Drugs & Targets FDA withdraws accelerated approval of infigratinib for metastatic cholangiocarcinoma with FGFR2 May 24, 2024Vol.50 No.21
